Insys Therapeutics files NDA at FDA for Dronabinol Oral Solution for Anorexia and Nausea.
Insys Therapeutics, Inc. a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, announced it has submitted a New Drug Application (NDA) to the FDA for its proprietary Dronabinol Oral Solution for Anorexia associated with weight loss in patients with AIDS; and Nausea and Vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol Oral Solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins